Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Pfizer
Shanghai Chest Hospital
Pfizer
M.D. Anderson Cancer Center
Second Affiliated Hospital of Nanchang University
Georgetown University
Eli Lilly and Company
Tianjin Medical University Cancer Institute and Hospital
City of Hope Medical Center
Prestige Biopharma Limited
Fundación GECP
Shanghai Pulmonary Hospital, Shanghai, China
Samsung Bioepis Co., Ltd.
Sun Yat-sen University
Ruijin Hospital
University of Rochester
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Tesaro, Inc.
Lebanese University
N.N. Petrov National Medical Research Center of Oncology
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
University of California, San Francisco
Intergroupe Francophone de Cancerologie Thoracique
Cambridge University Hospitals NHS Foundation Trust
Genentech, Inc.
Rutgers, The State University of New Jersey
ETOP IBCSG Partners Foundation
Case Comprehensive Cancer Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Eli Lilly and Company
Guangdong Association of Clinical Trials
Barbara Ann Karmanos Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Genentech, Inc.
M.D. Anderson Cancer Center
SWOG Cancer Research Network
SWOG Cancer Research Network
University Hospital Regensburg
Northwestern University
Swiss Cancer Institute